Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma
Autor: | Ryo Takagi, Tsutomu Kobayashi, Shin-ichi Fuchida, Kazuho Shimura, Nobuhiko Uoshima, Hiroto Kaneko, Junya Kuroda, Yuji Shimura, Taku Tsukamoto, Katsuya Wada, Masafumi Taniwaki, Mitsushige Nakao, Miki Kiyota, Kazuna Tanba, Chihiro Shimazaki, Isao Yokota, Shigeo Horiike, Yutaka Kobayashi, Hitoji Uchiyama, Yoshiaki Chinen |
---|---|
Rok vydání: | 2020 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty Malignancy 03 medical and health sciences 0302 clinical medicine immune system diseases hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols Epidemiology medicine Humans Risk factor Adverse effect Retrospective Studies business.industry Neoplasms Second Primary Hematology Second primary cancer medicine.disease humanities Standardized mortality ratio 030220 oncology & carcinogenesis Rituximab Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma 030215 immunology medicine.drug |
Zdroj: | Leukemia & Lymphoma. 61:3378-3386 |
ISSN: | 1029-2403 1042-8194 |
Popis: | Extended post-therapy long-term survival of patients with diffuse large B cell lymphoma (DLBCL) may also lead to an increase of late adverse events. We retrospectively investigated the frequency and clinical manifestation of second primary malignancy (SPM) after rituximab-containing immunochemotherapy in patients with DLBCL treated at seven institutes belonging to the Kyoto Clinical Hematology Study Group (KOTOSG) from the perspective of the existence of past or synchronous cancer history. In a median follow-up period of 899 days, 69 SPMs were observed in 58 of 809 patients. The most frequent SPM was gastric cancer, followed by lung cancer and colorectal cancer. The cumulative incidence of SPM increased steadily over time and was not significantly influenced by the presence or absence of past or synchronous cancer history. Our study suggests the need for careful attention to SPM in patients with DLBCL in daily practice. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |